Clinical trials in China

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

This study is testing new combination medicines, BNT326 and BNT327, for people with advanced non-small cell lung cancer. It aims to find a safe dose and see how well they work, both for those who've had previous treatments and those who haven't.

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

This study looks at a new medicine called zilebesiran for people with high blood pressure that isn't well controlled, especially if they also have heart problems or are at high risk of developing them. The aim is to see if zilebesiran can reduce serious heart-related events like heart attacks or strokes.

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

This study looks at a new daily pill, enlicitide decanoate, for people at high risk of heart problems like heart attacks or strokes. It aims to see if this pill can help reduce these serious events safely, compared to a dummy pill.

A Study of Daratumumab

This study offers ongoing access to specific treatments for people with multiple myeloma or smouldering multiple myeloma who have already benefited from them in previous studies. It helps ensure continued care and collects long-term safety information.

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

This study is looking into a new medicine, ALXN1850, for teenagers and adults with Hypophosphatasia (HPP). We want to see if it helps with daily activities compared to a dummy medicine (placebo). This is for people who haven't tried a similar treatment called asfotase alfa before.

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

This study is testing a new medicine called olpasiran to see if it can help people with heart disease and high levels of a specific fat in their blood, called Lp(a). We want to find out if olpasiran can lower the risk of heart attacks and other heart problems.

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

This study is testing a new medicine, Deucravacitinib, for adults with an active form of Sjögren's Syndrome. Researchers want to see if it's safe and effective compared to a dummy pill. It's a key step to finding better treatments for this autoimmune condition.

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

This study looks at a new drug, TAK-279, for people aged 18-75 with Crohn's disease that isn't well-controlled. We want to see if it reduces gut inflammation and is safe, compared to a dummy drug. It lasts about one year.

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This study looks at the long-term safety of a medicine called pirtobrutinib for people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It's for those already taking part in a previous pirtobrutinib study, to continue treatment and monitoring.

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

This study looks at a new drug, zasocitinib, for adults with psoriatic arthritis. It aims to see how well it works compared to a dummy drug. We're interested in people who have or haven't tried certain other treatments before.

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

This study is looking at a new way to treat a type of lung cancer called non-small cell lung cancer. It combines two medicines, amivantamab and capmatinib, to see how well they work together and what the best dose is.

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

This study looks at new treatments for a type of oesophageal cancer that hasn't spread after initial therapy. It tests two new medicines, tiragolumab and atezolizumab, to see if they can help stop the cancer from coming back or getting worse.

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

This study looks at a new medicine, BI 764198, for people aged 12 and over with a kidney condition called FSGS. It aims to see if this medicine helps improve kidney health. Participants will take a tablet daily and have their kidney function checked regularly.

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

This study looks at two medicines, upadacitinib and adalimumab, for adults with moderate to severe Rheumatoid Arthritis (RA). It checks how safe and effective they are. Upadacitinib is a pill, and adalimumab is an injection. This helps us understand which treatment works best.

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

This study looks at a new drug, Luspatercept, for people with myelofibrosis and anaemia who need regular blood transfusions and are already taking a JAK2 inhibitor. We want to see if it helps reduce the need for transfusions.

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

This study looks at new drug combinations for a type of lung cancer called Limited-Stage Small Cell Lung Cancer (LS-SCLC). Researchers want to see if adding pembrolizumab and olaparib to standard treatments helps people live longer.

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

This study is testing new combinations of medicines for advanced liver cancer (hepatocellular carcinoma) that can't be cured with surgery. It compares different drug blends to a common treatment to see which works best and is safest.

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

This study compares two treatments for follicular lymphoma that has come back or not responded to previous treatments. It looks at a new drug, mosunetuzumab, combined with lenalidomide, versus a standard treatment, rituximab with lenalidomide, to see which works better and if they are safe.

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

This study looks at a drug called Olaparib for people in the UK with a specific type of breast cancer linked to a BRCA gene change. It aims to see if Olaparib, given after standard treatments, can help prevent the cancer from coming back.

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

This study looks at new treatments for advanced stomach or gullet cancer. It combines a new drug, ABBV-400, with existing chemotherapy and another new drug, Budigalimab. We want to find the safest and most effective dose and see how well it works.

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

This study is testing a new medicine called Afimkibart for people with moderate to severe ulcerative colitis. It aims to see how well it works and if it's safe compared to a dummy drug. The study is for adults aged 16 to 80 who haven't found existing treatments helpful.

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

This study looks at how ATTR amyloidosis affects people in real life. Researchers will collect information from existing medical records to understand how the condition progresses, how it's treated, and its impact on daily life and healthcare use.

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

This study is testing a new drug, iza-bren, for advanced triple-negative breast cancer or ER-low, HER2-negative breast cancer. It compares iza-bren with standard chemotherapy in patients who haven't had previous treatment for advanced disease and can't receive certain immunotherapy drugs.

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

This study looks at a new drug, zanidatamab, combined with chemotherapy, and sometimes another drug called tislelizumab. It aims to see if this treatment works better and is safer than standard chemotherapy for advanced stomach and gullet cancers that have HER2.

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

This study is testing a new medicine called sefaxersen for people with a kidney disease called IgA nephropathy. We want to see if it's safe and helps slow down kidney damage, especially for those at higher risk.

ABTECT - Maintenance

This study looks at a new drug, ABX464, for people with ulcerative colitis. It's for those who haven't responded well to other treatments. The study checks if ABX464 can help keep symptoms under control over a long time and if it is safe to use.

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

This study is looking into a new treatment called Trontinemab for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and helps improve or slow down symptoms compared to a dummy treatment (placebo).

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

This study is looking at a new medicine called icotrokinra for people with psoriatic arthritis. We want to see if it helps reduce joint pain and swelling, and if it's safe. Some people will get the new medicine, others a dummy medicine.

A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

This study is looking at a new medicine called Redasemtide for people who have recently had a stroke. It wants to see if the medicine is safe and if it helps people get better after a stroke.

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

This study compares a new drug, DS-1062a, with a standard chemotherapy, docetaxel, for advanced lung cancer. It's for people whose cancer has grown after previous treatments. We want to see if DS-1062a is safer and works better.

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

This study looks at the long-term safety of a treatment called astegolimab for people with a lung condition called COPD. It's for people who have already taken part in previous studies of this drug.

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study looks at new treatments for a type of lung cancer where standard treatment has stopped working. It compares a drug called Dato-DXd, alone or with osimertinib, against usual chemotherapy to see which helps patients live longer without their cancer getting worse.

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

This study looks at whether a new medicine called inclisiran, taken with your usual statin, can help slow down or stop the build-up of fatty deposits (plaque) in the arteries around your heart. We're studying people with early heart disease who haven't had a heart attack or stroke.

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

This study for advanced neuroendocrine cancer compares a new drug called obrixtamig with standard chemotherapy. It aims to see if adding obrixtamig helps people live longer and also tests a new device to measure a cancer marker.

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

This study looks at new drug combinations for advanced bladder cancer that hasn't been treated before. It compares them to standard chemotherapy to see if they're safer and work better.

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

This study is looking into a new medication called LP352 for Dravet Syndrome. We want to see if it can help reduce seizures and if it's safe for children and adults. Participants will either get LP352 or a dummy pill called a placebo.

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

This study is looking at whether a medicine called dupilumab can help adults with moderate to severe asthma keep their lungs working better over time. It compares dupilumab to standard asthma care to see if it can prevent lung function from getting worse. It's a long-term study.

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

This study compares a new medicine, pirtobrutinib, with ibrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It's for adults, some of whom may have had previous treatment, and some who are newly diagnosed, especially if they have a specific gene change.

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

This study looks at a new treatment called amlitelimab for moderate to severe eczema in people aged 12 and older. It aims to understand its safety and how well it works over a long time. It involves regular visits and lasts several years.

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

This study compares a new medicine, sacituzumab tirumotecan, with standard chemotherapy for endometrial cancer. It's for people whose cancer has returned or progressed after previous treatments (platinum-based chemotherapy and immunotherapy). Researchers want to see if the new medicine helps people live longer and keeps the cancer from getting worse.

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

This study looks at a new way to give a cancer drug called amivantamab, by injection under the skin instead of through a drip. It aims to see how well it works and if it's safe for people with advanced lung cancer, especially those with specific genetic changes.

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

This study is looking into a new medication called Lunsekimig for adults with asthma that is hard to control. It compares Lunsekimig to a dummy treatment (placebo) to see if it helps manage asthma better and if it's safe.

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

This study looks at new drug combinations (Dato-DXd with rilvegostomig) for a type of advanced lung cancer. It compares them to a standard treatment, pembrolizumab, to see if they work better and are safe as a first treatment option.

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

This study is comparing two treatments, belzutifan plus pembrolizumab, against pembrolizumab alone, for kidney cancer that has been removed. It aims to see if the combination treatment can prevent the cancer from returning.

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

This study looks at a new medicine, sacituzumab tirumotecan, for advanced stomach or oesophagus cancer. It compares this new medicine to standard treatments to see if it's safer and works better for patients who have already had other treatments.

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

This study looks at a new drug, capivasertib, combined with standard treatment (abiraterone and ADT) for men with prostate cancer that has spread and is sensitive to hormone treatment. It's for men whose cancer has a specific change called PTEN deficiency.